El interés en corto de PureCycle Technologies da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de PureCycle Technologies. Los datos de interés en corto se actualizan cada dos semanas.

PureCycle Technologies (NASDAQ:PCT) Bolsa, Informe de interés en corto

PureCycle Technologies

PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies Inc

PACT GROUP HLDGS UNSP/ADR by Pact Group Holdings Ltd

Pact Group Holdings Ltd

PCTEL Inc

PCT Ltd

PICTON PPTY INCOME LTD by Picton Ppty Income Ltd.

Paylocity Holding Corporation - Common Stock

Paylocity Holding Corp

BRAVERN VENTURES LTD by Bravern Ventures Ltd

Bravern Ventures Ltd

Truist Securities analyst Joel Fishbein maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Hold and raises the price target from $92 to $100.

News

Price Target

Analyst Ratings

OKTA

Truist Securities Maintains Hold on Okta, Raises Price Target to $100

Shares of Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) continue to trend lower Tuesday. The stock was trading higher in the pre-market Monday, but the bears ended up overpowering the bulls. By the close, Alcoa <a href="https://www.benzinga.com/government/regulations/25/02/43592144/us-steel-aluminum-stocks-rally-as-trump-revives-25-tariff-plan">had lost almost 6%.</a>
Traders are watching the $28 level for a potential reversal. It has been support in the past. This is why it is our Stock of the Day.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04120155/aa-chart-1024x548.png" alt="" class="wp-image-808623" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04120155/aa-chart-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04120155/aa-chart-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04120155/aa-chart-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04120155/aa-chart.png 1519w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The $28 level provided support in early August and early September. As you can see on the chart, a move higher followed each time the shares reached this support level.
It may be about to happen again.
A number of the traders and investors who sold shares around $28 in August regretted their decision when the price moved higher. Some vowed to buy their shares back if they could eventually get them for the same price they were sold at.
Read Also: <a href="https://www.benzinga.com/25/03/44106754/targets-q4-earnings-beat-estimates-warns-consumer-uncertainty-impact-in-q1-profits">Target CEO Cautions Tariffs Will Pressure FY25 Profit, Consumer Uncertainty To Hit Feb Sales</a>
When the stock dropped back to around $28 in September, these remorseful sellers placed buy orders. There were so many of them that it created support at the level again. If the current downtrend reaches that level, Alcoa may find support once more.
There is also a chance another move higher follows.
Support is a price level at which there is a large amount of buy interest. There are at least as many or more shares to be bought than there are to be sold. This is why moves lower pause or halt when they reach support. Sellers can sell as much as they want without lowering the price.
Sometimes, some of the people who want to buy become anxious. They can sense the presence of the other buyers and become concerned they will be willing to pay a higher price. These are the people the sellers would go to.
They decide to increase the prices they are willing to pay so they don't miss out.
Other anxious buyers see this and decide to increase their bid price as well. This could result in a bidding war that forces the stock higher. If Alcoa reaches $28, it may happen again.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Photo: Vladimir Mulder/Shutterstock.com

Technicals

Trading Ideas

Stock Of The Day: Traders Watch Key Reversal Level On Alcoa

Starting Tuesday, U.S. President Donald Trump vowed to impose a 25% tariff on imported goods from Mexico and Canada and to double tariffs on <a target="_blank" href="https://www.benzinga.com/news/global/25/02/44010093/trumps-plan-for-canada-mexico-china-tariffs-to-start-march-4-could-shake-stock-market" rel="noreferrer noopener">those from China to 20%</a>.
Some GDP forecasts have turned negative, and consumer spending unexpectedly fell in January, raising concerns about economic growth. Inflation remains stubborn, with January's Consumer Price Index rising 3%, <a target="_blank" href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets" rel="noreferrer noopener">exceeding economists' expectations</a>.
Tariffs could push prices even higher since they typically raise costs. Canada, Mexico, and China have warned they will respond with their own tariffs, increasing the risk of a trade war. If inflation stays above the Federal Reserve's 2% target, interest rates may stay high for longer than anticipated.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44114754/stock-market-sell-off-history-shows-sp-500-rebounds-after-big-drops" rel="noreferrer noopener">Stock Market Sell-Off: History Shows S&amp;P 500 Rebounds After Big Drops</a>
On Tuesday, Mexican President Claudia Sheinbaum said there was no justification for Trump's 25% tariffs on imports from Mexico and that her government would respond with tariff and non-tariff measures.
"There is no reason, rationale or justification to support this decision that will affect our people and nations &#8230; Nobody wins with this decision,"
Mexico decided to wait until Sunday.
Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-04/mexico-s-sheinbaum-to-announce-trump-counter-measures-sunday?srnd=homepage-americas&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a> that the Mexican peso slumped as much as 1.5% against the U.S. dollar on Tuesday.
Mexico ETFs, iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) and Franklin FTSE Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLMX#NYSE">FLMX</a>) were down 2.47% and 2.73%, respectively.
Trump <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/03/fact-sheet-president-donald-j-trump-proceeds-with-tariffs-on-imports-from-canada-and-mexico/" rel="noreferrer noopener">said</a> Monday that Mexico, Canada, and China haven't done enough to stop fentanyl and its chemicals from reaching the U.S. In response, Sheinbaum said Mexico has worked with the U.S. on migration, security, and drug trafficking efforts.
The Mexican president dismissed the claim as "offensive, baseless, and defamatory," AP News wrote.
She then <a target="_blank" href="https://apnews.com/article/trade-war-mexico-trump-9cefdded035a0b35e700a7ba0bfc34b4" rel="noreferrer noopener">highlighted</a> her administration's efforts against drug cartels, mentioning the seizure of over a ton of fentanyl and the shutdown of 329 meth labs. She also pointed out that Mexico recently extradited 29 cartel members to the U.S.
On Tuesday, China hit back at Trump's recent tariff hikes by placing its own tariffs on certain U.S. goods, sanctioning American companies, and planning to file a complaint with&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44110625/us-firm-illumina-faces-setback-as-china-blocks-imports-amid-escalating-trade-war" rel="noreferrer noopener">the World Trade Organization</a>.
Beijing has imposed a 15% tax on American poultry, wheat, corn, and cotton in response to the U.S. doubling tariffs on Chinese products. A 10% tariff will also apply to soybeans, pork, beef, and other food items.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says" target="_blank" rel="noreferrer noopener">Trump Tariffs Will Raise Prices ‘Within Days,' Target CEO Says</a></li>
</ul>
Image via Shutterstock

Government

Politics

Markets

General

FLMX

MEXX

After China, Mexico To Hit Back Against Trump's Tariffs, Raising Trade War Risks

Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $90 to $50.

NTLA

Truist Securities Maintains Buy on Intellia Therapeutics, Lowers Price Target to $50

Citigroup analyst Paul Diamond maintains Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) with a Buy and lowers the price target from $18 to $17.

Citigroup Maintains Buy on Permian Resources, Lowers Price Target to $17

Genius Sports Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44104526/genius-sports-reports-fourth-quarter-and-full-year-2024-results-and-announces-2025-outlook-for-21-" rel="noreferrer noopener">trading higher on Tuesday.</a>
The company reported fourth-quarter GAAP loss per share of 12 cents, missing the street view of 2 cents earnings. Quarterly sales of $175.53 million (up 38% year over year) marginally missed the analyst consensus estimate of $175.57 million.
Betting Technology, Content &amp; Services&nbsp;revenue increased 48% year-over-year to $128.2 million, driven primarily by growth in business with existing customers as a result of price increases on contract renewals and renegotiations.
Media Technology, Content &amp; Services&nbsp;revenue increased 4% year-over-year to $29.8 million, while Sports Technology &amp; Services revenue increased 47%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says" rel="noreferrer noopener">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a>
Group adjusted EBITDA margin expanded by 900 basis points year over year to 18.4% in the quarter under review.
Group net loss was $28.2 million in the fourth quarter, representing a $10.2 million improvement compared to the $38.5 million loss in the fourth quarter ended December 31, 2023.
Group Adjusted EBITDA was $32.4 million in the quarter, representing a 171% increase from the year-ago period.
&#8220;We have consistently exceeded expectations, bolstered our technology advantage, and strengthened our balance sheet, now positioning Genius Sports for continued success in 2025 and a clear path to achieve greater scale,&#8221; said Mark Locke, Genius Sports Co-Founder and CEO.
Outlook: Genius Sports expects to generate group revenue of approximately $620 million (consensus $589.71 million) and group adjusted EBITDA of <a href="https://www.benzinga.com/calendars/guidance">approximately $125 million in 2025. </a>
The company exited the quarter with cash and equivalents worth $135.24 million.
Price Action: GENI shares are trading higher by 6.07% to $8.825 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts" target="_blank" rel="noreferrer noopener">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Guidance

Movers

GENI

Genius Sports Q4 Results: Sales Jump, Margins Expand & More

Strengthening U.S. Innovation and Advancing the Open RAN Ecosystem
&nbsp;
BOCA RATON, Fla.--(<a href="https://www.businesswire.com/">BUSINESS WIRE</a>)--Airspan Networks, a leading provider of wireless network solutions, today announced that it has signed an agreement to acquire Jabil's Open RAN radio portfolio and associated Intellectual Property Rights (IPR). This strategic acquisition expands Airspan's capability in high power macro radio development.
The acquisition brings a range of single, dual, and triple band macro radios, designed to support global operators across multiple spectrum bands. This portfolio contributes to Airspan's long-term product evolution and innovation in a rapidly growing market.

Asset Sales

Airspan Network Signs Agreement To Acquire Jabil's Open Ran Radio Portfolio And Associated Intellectual Property Rights, Expanding Its Capability In High Power Macro Radio Development; No Financial Terms Disclosed

Truist Securities analyst Tobey Sommer maintains Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) with a Buy and raises the price target from $165 to $180.

HURN

Truist Securities Maintains Buy on Huron Consulting Gr, Raises Price Target to $180

Shares of MongoDB Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) rose in early trading on Tuesday, ahead of its fourth-quarter results to be reported on Wednesday, March 5.
The company is likely to report in-line or marginally better fourth-quarter results and guide to subscription revenue growth of around 18% for fiscal 2026, according to Rosenblatt Securities.
The MongoDB Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60081c88879cba00010420fb/blair-abernethy">Analyst Blair Abernethy</a> reaffirmed a Buy rating and price target of $350.
The MongoDB Thesis: The company is likely to report quarterly total revenue of $517 million, slightly short of the consensus, while coming in-line with the guidance range, Abernethy said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"We expect Mongo's Subscriptions Revenue to grow 13% Y/Y to $502m (97% of Total Revenue) and Services Revenue to $15m (growth of 15% Y/Y)," Abernethy added.
MongoDB could report earnings of 67 cents per share, beating consensus of 66 cents per share, the analyst stated.
"We believe the enterprise database spending environment, legacy application migrations, and next generation AI application development activity in Q4 have remained relatively stable drivers for Mongo," he wrote.
"We continue to watch Mongo's Cloud-based Atlas adoption as it generates most of its revenue and growth from consumption charges for Atlas." 
MDB Price Action: Shares of MongoDB had declined by 4.33% to $247.80 at the time of publication on Tuesday.
Read More: &nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44071957/us-stocks-likely-to-open-higher-as-wall-street-watches-trutariff-talks-march-april-may-tend-to-be-solid-months-in-post-election-years-says-expert">&nbsp;Market Momentum: 3 Stocks Poised for Significant Breakouts</a>
Photo: Shutterstock

MongoDB Q4 Preview: In-line Or Marginally Higher Results Expected By Bullish Analyst

Citigroup analyst Paul Diamond maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Buy and lowers the price target from $160 to $135.

CHRD

Citigroup Maintains Buy on Chord Energy, Lowers Price Target to $135

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.edf-re.com&amp;esheet=54218888&amp;newsitemid=20250304339415&amp;lan=en-US&amp;anchor=EDF+Renewables+North+America&amp;index=1&amp;md5=228dd0a0d78a26aae913214dc5145168">EDF Renewables North America</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.masdar.ae&amp;esheet=54218888&amp;newsitemid=20250304339415&amp;lan=en-US&amp;anchor=Abu+Dhabi+Future+Energy+Company+%26%238211%3B+Masdar&amp;index=2&amp;md5=26329b6088cf8c3f9a2fbb2dedf0bc26">Abu Dhabi Future Energy Company &ndash; Masdar</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.edf-re.com%2Fpress-release%2Fmasdar-and-edf-renewables-agree-to-partner-in-eight-renewable-energy-projects-in-united-states%2F&amp;esheet=54218888&amp;newsitemid=20250304339415&amp;lan=en-US&amp;anchor=co-owners+of+the+Las+Majadas+Wind+Project&amp;index=3&amp;md5=3cb08e6db95a484f6e677d68f7fdca4a">co-owners of the Las Majadas Wind Project</a>, have entered into a power purchase agreement (PPA) with data center developer and operator Soluna Holdings, Inc. (Soluna), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>).
&nbsp;
Under the terms of the agreement, Soluna will purchase up to 166 megawatts (MW) of energy produced by the Las Majadas Wind Project to power a Soluna data center to be built close to the wind project&#39;s substation.

Contracts

SLNH

EDF Renewables North America And Masdar Agrees To Power Purchase Agreement With Soluna Holdings; Soluna Will Purchase Up To 166 Megawatts Of Energy Produced By The Las Majadas Wind Project To Power A Soluna Data Center To Be Built Close To The Wind Project's Substation

Raymond James analyst Andrew Marok maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Outperform and lowers the price target from $30 to $27.

Raymond James Maintains Outperform on Viant Technology, Lowers Price Target to $27

Twilio enables Cedar to streamline communications, elevating patient service and reducing provider costs with AI-driven automation and empathetic support
Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>), the customer engagement platform that drives real-time, personalized experiences for leading brands, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cedar.com%2F%3Futm_source%3Dpress-release%26utm_medium%3Dpr%26utm_campaign%3DPR%26utm_content%3Dwp&amp;esheet=54218435&amp;newsitemid=20250304590428&amp;lan=en-US&amp;anchor=Cedar&amp;index=1&amp;md5=0bb07910cc48cc4294df65019a542dd5">Cedar</a>, the leading patient financial experience platform for healthcare providers, today announced Twilio is powering Cedar's patient communications across SMS and Voice, including via Twilio's AI-powered ConversationRelay service, with the goals of improving the patient financial experience, driving operational efficiency and delivering cost reduction.
Navigating healthcare bills can be overwhelming, particularly for patients managing multiple providers or facing the burden of being uninsured. Simultaneously, healthcare providers are inundated with thousands of daily inquiries from patients seeking clarity on their financial obligations, driving up administrative costs. Cedar is addressing this systemic challenge by leveraging Twilio's scalable communications technology, seamlessly integrating it into its platform to enhance accessibility, streamline patient interactions, and create a more intuitive financial experience—while also reducing operational expenses for providers.
Cedar is leveraging Twilio's flexible and innovative solutions to build an AI-powered patient financial experience, including:
<ul>
<li>Streamlined Communication: Cedar utilizes Twilio's SMS capabilities to enhance bill notifications and appointment reminders, ensuring patients receive timely and effective updates.</li>
<li>Seamless Payment Experience: By integrating Twilio's Voice API and Stripe Pay Connector, Cedar enables patients to make secure payments over the phone with interactive voice response (IVR), including support for Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA). With <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ebri.org%2Fhealth%2Fcontent%2Fvital-statistics-on-flexible-spending-accounts--2022--forfeitures-on-the-rise&amp;esheet=54218435&amp;newsitemid=20250304590428&amp;lan=en-US&amp;anchor=roughly+half+of+FSA+account+holders+forfeiting+funds&amp;index=2&amp;md5=3442c7b8a59c2b9c859ab57404e2ebf1">roughly half of FSA account holders forfeiting funds</a> due to lack of awareness, this will help patients maximize available resources.</li>
<li>Smart and Personalized Patient Support: Built on Twilio's ConversationRelay service, Cedar later this year will be able to automate inbound patient billing calls with AI-powered voice agents that provide quick answers, reduce wait times, and improve satisfaction.</li>
</ul>
Twilio's ConversationRelay service, which enables developers to create robust natural voice AI agents by seamlessly integrating real-time streaming, speech recognition, and interruption handling, will support HIPAA-eligible use cases in the coming weeks for healthcare providers.

TWLO

Twilio Collaborates With Cedar to Enhance Patient Service And Reduce Costs Through AI-Driven Communication Tools

With latest transaction, Wellvana supports primary care providers across 40 states, serving approximately 1 million patients.
NASHVILLE, Tenn., and WOONSOCKET, R.I., March 4, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4375063-1&amp;h=266419207&amp;u=http%3A%2F%2Fwww.wellvana.com%2F&amp;a=Wellvana">Wellvana</a> and CVS Health&#xAE; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) today announced that Wellvana has acquired the Medicare Shared Savings Program (MSSP) business of CVS Accountable Care&#x2122;, part of CVS Health, in an all-stock transaction, giving CVS Health a strategic minority investment in Wellvana.&nbsp;

CVS Health Announces That Wellvana Has Acquired The Medicare Shared Savings Program Business Of CVS Accountable Care, Part Of CVS Health, In An All-Stock Transaction; Detailed Terms Have Not Been Disclosed

Citigroup analyst Paul Diamond maintains Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) with a Buy and lowers the price target from $14.5 to $12.

TALO

Citigroup Maintains Buy on Talos Energy, Lowers Price Target to $12

Shares of On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) were rising in early trading on Tuesday, after the company reported <a href="https://www.benzinga.com/25/03/44105269/performance-sportswear-maker-ons-q4-sales-jump-on-increased-brand-awareness-stocks-rise">strong fourth-quarter sales growth</a>.
Here are some key analyst takeaways.
<ul>
<li>Telsey Advisory Group <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5f9ab74825a7ef0001015b59/cristina-fernandez">analyst Cristina Fernández</a> maintained an Outperform rating and price target of $67.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee56ee7bf6000154d12e/tom-nikic">analyst Tom Nikic</a> reaffirmed a Buy rating and price target of $67.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Telsey Advisory Group: The company ended 2024 on a strong note. All metrics came in slightly above expectations. The company expects its revenue growth in 2025 to be frontend-loaded, Fernández said in the note. The company's fourth-quarter sales growth of 36% came in higher than consensus of 33%. Gross margins surged to a record high of 62.1%, she added.
While management's 2025 revenue and gross margin guidance came in slightly short of expectations, the company "tends to provide guidance it can exceed," the analyst stated.
"In addition, On commented 2025 is off to a good start and given the timing of product launches, such as Cloud 6 in February, expects 1H25 revenue growth to be higher than in 2H25," she further wrote.
Needham: With strong product innovation in 2024, On Holding is gearing up for a slew of product launches in 2025. This could drive sales, Nikic said. The company's brand awareness has grown, he added.
On Holding has "increasingly become a sneaker of choice for Gen Z consumers," he added.
Although the EMEA (Europe, the Middle East and Africa) region grew sluggishly through most of 2024, sales growth here accelerated from 15% in the third quarter to 33% in the fourth quarter, the analyst stated. "ONON remains one of the highest-momentum names in our coverage, and we remain bullish based on growing brand awareness, distribution expansion (both in DTC and wholesale), a strong margin profile, and a cash-rich balance sheet," he further wrote.
ONON Price Action: Shares of On Holding had risen by3.26% to $49.41 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44071957/us-stocks-likely-to-open-higher-as-wall-street-watches-trutariff-talks-march-april-may-tend-to-be-solid-months-in-post-election-years-says-expert">Market Momentum: 3 Stocks Poised for Significant Breakouts</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Reiteration

ONON

On Holding Posts Record High Q4 Margins, Analyst Praises Gen Z's 'Sneaker Of Choice'

Deep-pocketed investors have adopted a bearish approach towards Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 109 extraordinary options activities for Goldman Sachs Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 53% bearish. Among these notable options, 55 are puts, totaling $5,655,452, and 54 are calls, amounting to $3,798,684.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $800.0 for Goldman Sachs Group over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Goldman Sachs Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Goldman Sachs Group's whale trades within a strike price range from $210.0 to $800.0 in the last 30 days. 
<h3>Goldman Sachs Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741107677_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.45</td>
<td>$62.55</td>
<td>$63.0</td>
<td>$580.00</td>
<td>$233.1K</td>
<td align="right">441</td>
<td align="right">374</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$15.25</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$340.00</td>
<td>$171.8K</td>
<td align="right">5</td>
<td align="right">214</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$24.65</td>
<td>$24.2</td>
<td>$24.56</td>
<td>$525.00</td>
<td>$159.8K</td>
<td align="right">220</td>
<td align="right">65</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$49.15</td>
<td>$47.05</td>
<td>$49.15</td>
<td>$600.00</td>
<td>$152.3K</td>
<td align="right">162</td>
<td align="right">32</td>
</tr>
<tr>
<td>GS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$29.0</td>
<td>$28.85</td>
<td>$29.0</td>
<td>$575.00</td>
<td>$150.8K</td>
<td align="right">141</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Goldman Sachs Group</h3>
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
After a thorough review of the options trading surrounding Goldman Sachs Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Goldman Sachs Group Standing Right Now?</h3>
<ul>
<li>With a volume of 1,885,086, the price of GS is down -5.33% at $573.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Goldman Sachs Group</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $720.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Goldman Sachs Group, which currently sits at a price target of $720. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Goldman Sachs Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Goldman Sachs Group: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $67,500, and 10 are calls, for a total amount of $496,525.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $260.0 to $340.0 for Amgen over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $260.0 to $340.0 in the last 30 days. 
<h3>Amgen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741107671_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$19.35</td>
<td>$18.35</td>
<td>$18.79</td>
<td>$300.00</td>
<td>$94.6K</td>
<td>1.1K</td>
<td align="right">55</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$23.6</td>
<td>$21.2</td>
<td>$21.87</td>
<td>$297.50</td>
<td>$91.8K</td>
<td>12.1K</td>
<td align="right">42</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$66.55</td>
<td>$64.8</td>
<td>$64.8</td>
<td>$260.00</td>
<td>$64.8K</td>
<td>171</td>
<td align="right">10</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$22.25</td>
<td>$20.95</td>
<td>$21.75</td>
<td>$340.00</td>
<td>$43.5K</td>
<td>125</td>
<td align="right">20</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$16.75</td>
<td>$16.5</td>
<td>$16.5</td>
<td>$320.00</td>
<td>$41.2K</td>
<td>2.0K</td>
<td align="right">28</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Where Is Amgen Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,336,050, the price of AMGN is up by 1.95%, reaching $316.85.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On Amgen</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $302.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Amgen, targeting a price of $329. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Amgen with a target price of $275. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

AMGN

Behind the Scenes of Amgen's Latest Options Trends

Financial giants have made a conspicuous bullish move on Lemonade. Our analysis of options history for Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) revealed 10 unusual trades.
Delving into the details, we found 60% of traders were bullish, while 20% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $337,085, and 5 were calls, valued at $281,488.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $75.0 for Lemonade during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Lemonade's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Lemonade's significant trades, within a strike price range of $30.0 to $75.0, over the past month.
<h3>Lemonade Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741107665_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/28/25</td>
<td>$12.2</td>
<td>$11.8</td>
<td>$12.0</td>
<td>$45.00</td>
<td>$180.0K</td>
<td>150</td>
<td align="right">150</td>
</tr>
<tr>
<td>LMND</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.5</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$75.00</td>
<td>$133.2K</td>
<td>1.4K</td>
<td align="right">172</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$12.2</td>
<td>$11.8</td>
<td>$12.0</td>
<td>$42.00</td>
<td>$60.0K</td>
<td>61</td>
<td align="right">50</td>
</tr>
<tr>
<td>LMND</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$6.6</td>
<td>$6.4</td>
<td>$6.5</td>
<td>$50.00</td>
<td>$52.0K</td>
<td>328</td>
<td align="right">242</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$7.4</td>
<td>$35.00</td>
<td>$37.0K</td>
<td>402</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About Lemonade</h3>
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
After a thorough review of the options trading surrounding Lemonade, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Lemonade's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,126,702, the price of LMND is down by -5.9%, reaching $33.64.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Lemonade</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $47.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Citizens Capital Markets downgraded its rating to Market Outperform, setting a price target of $60. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Lemonade, maintaining a target price of $34. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lemonade options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

LMND

This Is What Whales Are Betting On Lemonade

IPOs

Skycorp Solar Group Shares Open For Trade At $3.69/Share; IPO Priced At $4/Share On 2M Shares

Press Releases

PureCycle Announces Financing Transaction and Ironton Production Update

PureCycle Processes One Million Pounds in a Week at Ironton Facility

PureCycle Schedules Third Quarter 2024 Corporate Update

PureCycle Provides Third Quarter 2024 Corporate Update

Drake Purchases PureCycle Resin Following Successful Production of Continuous Filament Yarns

PureCycle Announces Financing Transaction for $33 Million

Churchill Introduces "Run It Back" Line of Cups & Containers Made with Recycled PureFive(TM) Resin

PureCycle Schedules Fourth Quarter 2024 Corporate Update

PureCycle Technologies Fourth Quarter and Fiscal Year Ending 2024 Update

PureCycle Announces Preliminary Court Approval of Shareholder Derivative Settlement

AdvanSix

Braskem

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

Crown Electrokinetics Corp. - Common Stock

Crown ElectroKinetics

Gulf Resources

Hawkins

Koppers Holdings

Kronos Worldwide

Loop Industries

Mativ Holdings

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Mat

Tantech Hldgs

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Comments

PureCycle Technologies

Interés en corto

PureCycle Technologies (NASDAQ:PCT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL